9th Neurodegenerative Drug Development Summit 2021

Memo

Whether you are working in a team dedicated to Parkinson’s, Alzheimer’s, Lewy Body Dementia or a rare neurodegenerative disorder, this intimate, industry-led forum is not only an opportunity to learn from those pioneering this space, but to network and build meaningful partnerships with over 150 neurodegenerative drug development experts. After all, collaboration in this industry is pivotal! Across 3 action-packed, case-study driven days, and 2 parallel tracks of learning, we present the opportunity to join us online in 2021 to overcome the challenges preventing you and your team from translating promising preclinical research into evidenced clinical benefit. The digital agenda will address the following hot topics and translational challenges: Discover diverse approaches to regeneration therapeutics with Aspen Neuroscience and Neuronascent, and explore cellular approaches to neurodegenerative drug discovery with Noveome Hear novel approaches to developing protein misfolding-specific therapies for the treatment of neurodegeneration with ProMis Neurosciences and Origami Therapeutics Evaluate pioneering approaches to clinical design for ALS with Harvard Medical School and hear how Roche are targeting Alpha-Synuclein to design the next-generation of clinical trials Investigate post-translational modifications as a new therapeutic approach for CNS disorders with Circumvent Pharmaceuticals and hear how Stoke Therapeutics are developing a unique therapeutic approach to tackle neurodegenerative disorders using antisense oligonucleotides Explore the implementation of novel blood-based biomarkers, evaluate the role of CNS exosomes in diagnosing AD and PD and assess an encyclopedia of available biomarkers for neurodegenerative diseases with Zetterberg, the EMA, Eli Lilly and Company, Rissman and Teunissen Unpack the role that genetics play in neurodegenerative diseases and explore emerging new gene therapies for CNS indications with Eisai and Brain Neurotherapy Bio With its most discussion-led format yet, the Neurodegenerative Drug Development provides unrivalled networking opportunities for you to catch up with friendly faces and make new connections to establish future partnerships. On Tuesday February 23, 2021 at 9:00 am (ends Thursday February 25, 2021 at 5:00 pm) Prices: Drug Developer - Conference Only: USD 1799.00,Drug Developer - Conference + 1 Workshop: USD 2098.00,Drug Developer - Conference + 2 Workshops: USD 2397.00,Drug Developer - Conference + 3 Workshops: USD 2696.00,Drug Developer - Conference + 4 Workshops: USD 2995.00,Solution Provider - Conference Only: USD 2339.00,Solution Provider - Conference + 1 Workshop: USD 2698.00,Solution Provider - Conference + 4 Workshops: USD 3595.00,Academic/Start Up - Conference Only: USD 1099.00,Academic/Start Up - Conference + 4 Workshops: USD 1895.00 URLs: Tickets: https://go.evvnt.com/698681-0?pid=5569 Brochure: https://go.evvnt.com/698681-3?pid=5569 Speakers: Andrew Lim, Chief Executive Officer, Circumvent Pharmaceuticals, Beth Hoffman, Founder, President and CEO, Origami Therapeutics, Charlotte Teunissen, Professor Neurochemistry, VUmc, Daniel Lorrain, CSO, Pipeline Therapeutics, Dimitry Ofengeim, Precision Neurology and Neuroinflammation, Head Sanofi, Don W Cleveland Chair, Distinguished Professor of Cellular and Molecular Medicine and Neurosciences Member, Ludwig Institute for Cancer Research, Elena H Martínez-Lapiscina, Rare Neurological Disorders Lead - Clinical Neurologist, European Medicines Agency, Gene Liau Executive, Vice President; Head Research and Preclinical Development, Stoke Therapeutics, Gennaro Pagano, Expert Medical Director, Group Leader in Early Development, and Chair of Medical Directors Fellowship, Roche Pharma and Early Development (pRED), Henrik Zetterberg, Professor, University of Gothenburg, Howard Federoff, Chief Executive Officer, Aspen Neuroscience, Isaac Veinbergs, President and CEO, Libra Therapeutics, Janna Hutz, Head of Discovery Data Science, Eisai Center for Genetics Guided Dementia Discovery (G2D2), Jeff Dage Senior Research Advisor, Eli Lilly and Company, Jonathan Behr, Partner Dementia Discovery Fund, Jonathan Levenson, Vice President of Translational Biology, Tiaki Therapeutics, José Luis, Molinuevo VP Clinical Development, Neurodegeneration Lundbeck, Judith Kelleher-Andersson, President and CEO, Neuronascent, Krystof Bankiewicz, President and Chief Executive Officer, CEO Brain Neurotherapy Bio, Columbus Children’s Foundation, Larry Brown, Executive Vice President and Chief Scientific Officer, Noveome Biotherapeutics, Mark Treherne, Chairman, Gen2 Neuroscience, Martin Tolar, Founder, President and CEO, Alzheon, Maurice Zauderer, President and CEO, Vaccinex, Michael Kurnellas, Staff Scientist, Alector, Michele Vendruscolo, Professor and CSO, Cambridge University Centre for Misfolding Diseases and Wren Therapeutics, Michelle Hastings Director, Center for Genetic Diseases, Professor Chicago Medical School, RFUMS, Neil Cashman CSO of ProMIS Neurosciences, Professor, Neurology University of British Columbia, Robert Rissman, Professor, UC San Diego, Sabrina Paganoni, Assistant Professor, Harvard Medical School, Sanjay Kakka, President and CEO, Tranquis Therapeutics, Selina Wray, Vanessa Almendro, Head of Strategy and Operations, Eisai Center for Genetics Guided Dementia Discovery (G2D2)